CD96 Expression on Hemopoietic Stem Cells in Acute Leukemia
|School||Huazhong University of Science and Technology|
|Course||Internal Medicine Hematology|
|Keywords||CD96 flow cytometry Leukemia stem cell|
Objective This study was aimed to investigate the expression of CD96 leukemia stem cells in 91 patients with acute leukemia, and the results were analyzed with clinical pathological data.Methods Flow cytometry was used to detect CD96 molecule on the bone marrow mononuclear cell surface of 91 newly diagnosed patients with acute leukemia, and 15 healthy adults were served as normal controls.Results The average rate of CD96 expression was （53.27±14.43） % in B-ALL stem cells (CD45+ CD34+ CD19+); （87.54±10.02） % in T-ALL stem cells (CD45+ CD34+ CD7+); and （49.88±5.68） % in AML stem cells (CD45+CD34+CD38- ); which was significant difference compared with healthy controls （0.65±0.59） %. After treatment, compared CD96+ group CR rate（52%）and CD96+ group NR rate （10.6%）with healthy controls, which had significant difference. CD96 average rate in stem cells were detected after treatment. Compared CD96+ CR group （1.68±2.31）% with healthy controls, which had no difference. However, compared CD96+ NR group （62.39±26.29）% with healthy controls, which had significant difference （p<0.05）.The leukocyte, hemoglobin and platelet count in CD96+ group had no obvious difference than CD96- ones. There was no change found in the field of molecular biology and cytogenetic between these two groups.Conclusion CD96 expression is different in different type of leukemia. The positive expression of CD96 on bone marrow hematopoietic stem cells in patients with acute leukemia may be associated with primary drug resistance, replase and progression. The CD96 in hematopoietic stem cells of AL could be a helpful prognostic indicator in treatment response assessment.